Biguanides and NIDDM
- PMID: 1600835
- DOI: 10.2337/diacare.15.6.755
Biguanides and NIDDM
Abstract
The main biguanides, metformin and phenformin, were introduced in 1957 as oral glucose-lowering agents to treat non-insulin-dependent diabetes mellitus (NIDDM). Phenformin was withdrawn in many countries because of an association with lactic acidosis, but metformin does not have the same risk if appropriately prescribed. Metformin is now widely used as a monotherapy and in combination with a sulfonylurea. Unlike sulfonylureas, metformin is not bound to plasma proteins, is not metabolized, and is eliminated rapidly by the kidney. The glucose-lowering effect occurs without stimulation of insulin secretion and results mainly from increased glucose utilization. The presence of insulin is required, and enhancement of insulin action at the postreceptor level occurs in peripheral tissues such as muscle. In peripheral tissues metformin increases insulin-mediated glucose uptake and oxidative metabolism. Metformin also increases glucose utilization by the intestine, primarily via nonoxidative metabolism. The extra lactate produced is largely extracted by the liver and serves as a substrate to sustain gluconeogenesis. This limits the extent to which metformin reduces hepatic glucose production but provides a safeguard against excessive glucose lowering. Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug. It does not cause weight gain, it helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties. Metformin offers a useful treatment for insulin-resistant overweight NIDDM patients.
Similar articles
-
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.J Fam Pract. 1996 Jun;42(6):612-8. J Fam Pract. 1996. PMID: 8656173 Review.
-
[Value of biguanide in therapy of diabetes mellitus].Med Klin (Munich). 1997 Aug 15;92(8):472-9, 505. doi: 10.1007/BF03044916. Med Klin (Munich). 1997. PMID: 9340472 Review. German.
-
[Therapeutic utility of biguanides in the treatment of NIDDM].Nihon Rinsho. 1999 Mar;57(3):657-62. Nihon Rinsho. 1999. PMID: 10199150 Review. Japanese.
-
Oral hypoglycemic agents in type II diabetes mellitus.Am Fam Physician. 1995 Nov 15;52(7):2075-8. Am Fam Physician. 1995. PMID: 7484707
-
Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.
Cited by
-
Role of metformin in the management of polycystic ovary syndrome.Ther Adv Endocrinol Metab. 2010 Jun;1(3):117-28. doi: 10.1177/2042018810380215. Ther Adv Endocrinol Metab. 2010. PMID: 23148156 Free PMC article.
-
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.Endocrine. 2003 Apr;20(3):215-8. doi: 10.1385/ENDO:20:3:215. Endocrine. 2003. PMID: 12721499 Clinical Trial.
-
Current management strategies for coexisting diabetes mellitus and obesity.Drugs. 2003;63(12):1165-84. doi: 10.2165/00003495-200363120-00001. Drugs. 2003. PMID: 12790691 Review.
-
Monitoring Patients on Metformin: Recent Changes and Rationales.J Pharm Technol. 2018 Feb;34(1):28-36. doi: 10.1177/8755122517747295. Epub 2017 Dec 10. J Pharm Technol. 2018. PMID: 34860984 Free PMC article. Review.
-
Older age and phenformin therapy: a dangerous association.Intern Emerg Med. 2008 Dec;3(4):401-3. doi: 10.1007/s11739-008-0154-y. Epub 2008 Apr 15. Intern Emerg Med. 2008. PMID: 18415028 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical